Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Lung cancer has a high mortality rate and is often diagnosed at the metastatic stage. Gefitinib is a targeted molecular therapeutic drug used to treat patients with non-small-cell lung cancer (NSCLC). Korean herbal medicines may also have therapeutic efficacy against lung cancer, reduce the side effects associated with chemotherapy, and improve patient quality of life (QOL). This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. The Korean herbal medicine regimen included woohwanggeosa- dan, hwanggibujeong-dan and geonchilgyebok- jeong. The computed tomography (CT) findings showed that following combination treatment, the size of the tumor was markedly decreased without serious adverse events. Moreover, the Eastern Cooperative Oncology Group (ECOG) performance status was improved and cancer-related pain was decreased. These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. Further studies are needed to examine the mechanism and the clinical efficacy of Korean herbal medicines against NSCLC.
Abstract
Lung cancer has a high mortality rate and is often diagnosed at the metastatic stage. Gefitinib is a targeted molecular therapeutic drug used to treat patients with non-small-cell lung cancer (NSCLC). Korean herbal medicines may also have therapeutic efficacy against lung cancer, reduce the side effects associated with chemotherapy, and improve patient quality of life (QOL). This case report describes the effects of a Korean herbal medicine regimen combined with gefitinib in a patient with NSCLC and bone metastasis. The Korean herbal medicine regimen included woohwanggeosa- dan, hwanggibujeong-dan and geonchilgyebok- jeong. The computed tomography (CT) findings showed that following combination treatment, the size of the tumor was markedly decreased without serious adverse events. Moreover, the Eastern Cooperative Oncology Group (ECOG) performance status was improved and cancer-related pain was decreased. These results suggest that a combination of Korean herbal medicines and gefitinib may be an effective therapeutic option for patients with advanced NSCLC and bone metastasis. Further studies are needed to examine the mechanism and the clinical efficacy of Korean herbal medicines against NSCLC.
참고문헌 (14)
- Yang L, "Immunotherapy for lung cancer: advances and prospects", Am J Clin Exp Immunol, 5(1), pp.1~20 (2016)
- Ansari J, "Epigenetics in nonsmall cell lung cancer : from basics to therapeutics", Transl Lung Cancer Res, 5(2), pp.155~171 (2016)
- Li MJ, "Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients", Onco Targets Ther, 9, pp.1291~1302 (2016)
- 범승훈, "Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients", Cancer Research and Treatment, 48(1), pp.88~97 (2016), 대한암학회[DOI]
- Nguyen KS, "Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway", Clin Lung Cancer, 10(4), pp.281~289 (2009)
- Whang CY, "Bibliographic study on the therapy of lung cancer by integrated oriental and western medicine", J Korean Orient Med, 16(2), pp.177~194 (1995)
- Sun-Hwi Bang, "A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb", IV Non-small-cell Lung Cancer Treated with HangAm-Plus, 2012, pp.15(2), 31~35[DOI]
- Yim MH, "Soluble components of Hericium erinaceum induce NK cell activation via production of interleukin-12 in mice splenocytes", Acta Pharmacol Sin, 28(6), pp.901~907 (2007)
- Bi X, "Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt", beta-catenin signaling inhibition, 2014, pp.742, 145~152
- Cheon SH, "Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer", Forsch Komplementmed, 18(2), pp.77~83 (2011)
- Park SJ, "A case report of a clinically diagnosed advanced lung cancer patient after treatment with gunchilgyebok-jung", J Korean Tradit Oncol, 20(1), pp.23~29 (2015)
- Mok TS, "Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Yang XB, "Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial", Trials, 16, pp.146~ (2015)
- Yang XB, "Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study", Complement Ther Med, 22(6), pp.1010~1018 (2014)